Please use this identifier to cite or link to this item:
Title: Serous and mucinous borderline ovarian tumors: Are there real differences between these two entities?
Authors: Benito, Virginia
Lubrano, Amina
Arencibia, Octavio
Medina Ramos, Norberto Fidel 
Álvarez León, Eva Elisa 
Andújar, Miguel 
Falcón Juan, Miguel
Falcón, Orlando
UNESCO Clasification: 32 Ciencias médicas
320108 Ginecología
Keywords: Borderline ovarian tumor
Serous tumor
Mucinous tumor
Issue Date: 2010
Journal: European Journal of Obstetrics & Gynecology and Reproductive Biology 
Abstract: Objective To evaluate the clinical outcome and pathological features of patients with borderline ovarian tumors (BOT) with special emphasis on serous and mucinous histology. Study design Medical and anatomopathological records were reviewed in the Gynecological Oncology Department of the Canarian University Hospital between 1990 and 2005. Survival rates were analyzed by using the Kaplan–Meier technique. Results The study included 163 patients. Serous tumors corresponded to 68 cases and mucinous tumors to 91 cases. Eighty-nine percent of patients were at FIGO stage I, 1.2% at stage II and 9.8% at stage III. Serous histology was significantly related to the presence of peritoneal implants (22.4% vs 3.6%; p = 0.001), positive peritoneal cytology (35.7% vs 8.5%; p = 0.001) and bilaterality (27.9% vs 1.1%, p < 0.0001). Event-free survival (EFS) rates at 2, 5 and 10 years were 96.7%, 92.7% and 90.5%, respectively, with a mean survival time of 183 months (CI 95% 172–193). Thirteen recurrence cases were found (7.9%) with a mean time to recurrence of 39.6 months (range 4–140). Overall survival (OS) rates at 2, 5 and 10 years were 100%, 96.4% and 93.6%, respectively, with a mean time of 189 months (CI 95% 179–198). Mucinous BOT were associated with significantly lower OS rates than serous BOT (10 years OS: 88.5% vs 98.2%; p = 0.01). Conclusions Serous tumors present more unfavorable anatomopathological characteristics but are associated with better prognosis than mucinous tumors. If mucinous BOT diagnosis is retained physicians should be aware that their aggressive potential is not negligible.
ISSN: 0301-2115
DOI: 10.1016/j.ejogrb.2010.07.024
Source: European Journal of Obstetrics Gynecology and Reproductive Biology[ISSN 0301-2115],v. 153(2), p. 188-192 (Diciembre 2010)
Appears in Collections:Artículos
Show full item record


checked on Oct 1, 2023

Page view(s)

checked on May 20, 2023

Google ScholarTM




Export metadata

Items in accedaCRIS are protected by copyright, with all rights reserved, unless otherwise indicated.